YNYasushi Nakamori

Yasushi Nakamori

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yasushi Nakamori has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    First clinical experience with IVR-CT system in the emergency room: Positive impact on trauma workflow

    by Daiki Wada, Yasushi Nakamori, Kazuma Yamakawa, Satoshi Fujimi

    Recently, computed tomography (CT) has gained importance in the early diagnostic phase of trauma care in the emergency room. We implemented a new trauma workflow concept with CT in our emergency room that allows emergency therapeutic intervention without relocating the patient. Times from patient arrival to CT initiation, CT end, and definitive intervention were significantly shorter with our new protocol than were those with the conventional CT protocol. Our new workflow concept, which provides faster time to definitive intervention, appears to be effective.


  • Open Access

    Assessment of risk factors related to healthcare-associated methicillin-resistant Staphylococcus aureus infection at patient admission to an intensive care unit in Japan

    by Kazuma Yamakawa, Osamu Tasaki, Miyuki Fukuyama, Junichi Kitayama, Hiroki Matsuda, Yasushi Nakamori, Satoshi Fujimi, Hiroshi Ogura, Yasuyuki Kuwagata, Toshimitsu Hamasaki, et al.

    Healthcare-associated methicillin-resistant Staphylococcus aureus (HA-MRSA) infection in intensive care unit (ICU) patients prolongs ICU stay and causes high mortality. Predicting HA-MRSA infection on admission can strengthen precautions against MRSA transmission. This study aimed to clarify the risk factors for HA-MRSA infection in an ICU from data obtained within 24 hours of patient ICU admission.


  • Open Access

    Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study

    by Kazuma Yamakawa, Satoshi Fujimi, Tomoyoshi Mohri, Hiroki Matsuda, Yasushi Nakamori, Tomoya Hirose, Osamu Tasaki, Hiroshi Ogura, Yasuyuki Kuwagata, Toshimitsu Hamasaki, et al.

    Introduction: Cross-talk between the coagulation system and inflammatory reactions during sepsis causes organ damage followed by multiple organ dysfunction syndrome or even death. Therefore, anticoagulant therapies have been expected to be beneficial in the treatment of severe sepsis. Recombinant human soluble thrombomodulin (rhTM) binds to thrombin to inactivate coagulation, and the thrombin-rhTM complex activates protein C to produce activated protein C. The purpose of this study was to examine the efficacy of rhTM for treating patients with sepsis-induced disseminated intravascular coagulation (DIC). Methods: This study comprised 65 patients with sepsis-induced DIC who required ventilatory management. All patients fulfilled the criteria of severe sepsis and the International Society on Thrombosis and Haemostasis criteria for overt DIC. The initial 45 patients were treated without rhTM (control group), and the following 20 consecutive patients were treated with rhTM (0.06 mg/kg/day) for six days (rhTM group). The primary outcome measure was 28-day mortality. Stepwise multivariate Cox regression analysis was used to assess which independent variables were associated with mortality. Comparisons of Sequential Organ Failure Assessment (SOFA) score on sequential days between the two groups were analyzed by repeated measures analysis of variance. Results: Cox regression analysis showed 28-day mortality to be significantly lower in the rhTM group than in the control group (adjusted hazard ratio, 0.303; 95% confidence interval, 0.106 to 0.871; P = 0.027). SOFA score in the rhTM group decreased significantly in comparison with that in the control group (P = 0.028). In the post hoc test, SOFA score decreased rapidly in the rhTM group compared with that in the control group on day 1 (P < 0.05). Conclusions: We found that rhTM administration may improve organ dysfunction in patients with sepsis-induced DIC. Further clinical investigations are necessary to evaluate the effect of rhTM on the pathophysiology of sepsis-induced DIC.


  • Open Access

    A novel technique of differential lung ventilation in the critical care setting

    by Kazuma Yamakawa, Yasushi Nakamori, Satoshi Fujimi, Hiroshi Ogura, Yasuyuki Kuwagata, Takeshi Shimazu

    Differential lung ventilation (DLV) is used to salvage ventilatory support in severe unilateral lung disease in the critical care setting. However, DLV with a double-lumen tube is associated with serious complications such as tube displacement during ventilatory management. Thus, long-term ventilatory management with this method may be associated with high risk of respiratory incidents in the critical care setting.